SILCOLAPSE 910 is efficient in aqueous and non-aqueous media.
SILCOLAPSE 910 is normally used at low concentrations between 1 and 100 mg/kg (or per litre). In pulp and paper applications typical use rates for 10 % emulsions are 100-2000 grams per ton of pulp.
SILCOLAPSE 910 can be formulated:
Into an aqueous emulsion by using commercially available emulsifiers or silicone emulsifiers like BLUESIL SP 3300. SILCOLAPSE 910 can be added to others Elkem SILCOLAPSE compounds in order to improve performances. BLUESIL BOSTER 100 can also be used to increase defoaming performances of the compound.
For anhydrous media with solvents such as aliphatic, aromatic hydrocarbons, but also some ketones and alcohols when used in aqueous media.
Regulation compliancy: compliant with some Food Contact Regulations, please contact us if more information or certificates are requested. Contact your local Elkem Silicones Technical Services experts for any information.
|SILCOLAPSE 910 may be stored at a temperature below 40 °C/ 104 °F for up to 12 months from its date of manufacturing.||Please consult the Safety Data Sheet of this product.|
SILCOLAPSE 910 is a 100% active foam control agent.
SILCOLAPSE 910 is the latest generation of high performance foam control agent specially designed for aggressive foaming environments.
Easy handling and processing thanks to lowest viscosity
Excellent foam knockdown and persistency at low use amounts
Improved drainage in pulp washing process and reduced bleaching chemicals costs.
Suitable for both softwood and hardwood applications
Versatility for formulating aqueous dispersions and emulsions
High efficiency in alkaline conditions and at high temperature
Highly efficient compared to conventional organic oil-based antifoams
SILCOLAPSE 910 can be used as such or formulated into emulsions in different fields of use like:
Pulp industry: various processing steps particularly in chemical pulping operations (black liquor, waste water).
Oil & Gas industry: drilling, cementing.
Chemicals, cleaning, and waste water treatment.
Asia Pacific;Central and South America;Europe Middle East Africa;North America